Zentalis Pharmaceuticals IncNASDAQ:ZNTL
- LAST PRICE8.3900
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots6.2500/ 1
- Ask / Lots6.3000/ 2
- Open / Previous Close0.0000 / 8.3900
- Day Range---
- 52 Week Range
- Volume2,619,034
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ZNTL |
|---|---|---|
| 09:32 ET | 192652 | 6.2501 |
Today
DJ Zentalis Pharmaceuticals Shares Slide on Partial Clinical Holds on Cancer Drug Studies, from 2 hours ago by Dow Jones
2 hours ago by Dow JonesDJ Zentalis Pharmaceutical Studies on Partial Clinical Hold Following Deaths, from 2 hours ago by Dow Jones
2 hours ago by Dow JonesZentalis Pharmaceuticals Provides Update on Azenosertib Clinical Development Program, from 2 hours ago by Dow Jones
2 hours ago by Dow Jones
Jun 3, 2024
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), from 6:00PM ET on Monday Jun 03, 2024 by Dow Jones
6:00PM ET on Monday Jun 03, 2024 by Dow Jones
May 30, 2024
Zentalis Pharmaceuticals to Present at the Jefferies Global Healthcare Conference, from 7:00AM ET on Thursday May 30, 2024 by Dow Jones
7:00AM ET on Thursday May 30, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Zentalis Pharmaceuticals Inc | 595.8M | -2.5x | --- |
Mineralys Therapeutics Inc | 605.7M | -5.6x | --- |
Oculis Holding AG | 545.7M | -6.4x | --- |
Northwest Biotherapeutics Inc | 602.7M | -7.8x | --- |
Arrivent Biopharma Inc | 620.0M | 0.0x | --- |
PepGen Inc | 563.1M | -5.3x | --- |
Company Information
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company’s lead product candidate includes azenosertib (ZN-c3), which is a WEE1 inhibitor for advanced solid tumors and hematological malignancies. The Company is also developing a BCL-2 inhibitor, ZN-d5, for hematological malignancies and related disorders. ZN-d5 is being evaluated in combination with azenosertib in a Phase I/II dose escalation clinical trial in patients with R/R acute myeloid leukemia (AML) (ZN-d5-004C). The Company is also advancing its research on protein degraders and other undisclosed targets using its Integrated Discovery Engine.
Contact Information
- Headquarters
- 1359 Broadway, Suite 801NEW YORK, NY, United States 10018
- Phone
- 212-433-3791
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- David Johnson
- President, Executive Director
- Cam Gallagher
- President, Chief Executive Officer, Director
- Kimberly Blackwell
- Chief Financial Officer, Treasurer
- Melissa Epperly
- Chief Operating Officer
- Iris Roth
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $595.8M |
|---|---|
Revenue (TTM) | $40.6M |
Shares Outstanding | 71.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.76 |
EPS | $-3.36 |
Book Value | $6.18 |
P/E Ratio | -2.5x |
Price/Sales (TTM) | 14.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -639.35% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
